Yahoo Canada Web Search

Search results

1. www.bms.comGlobal Biopharmaceutical Company - Bristol Myers Squibb

   www.bms.com

   • Cached

   Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.

2. en.wikipedia.org › wiki › Bristol_Myers_SquibbBristol Myers Squibb - Wikipedia

   en.wikipedia.org › wiki › Bristol_Myers_Squibb

   • Cached

   The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.

3. BMY - Bristol-Myers Squibb Company

   Yahoo Finance

   • Range :
   • 1d
   • 5d
   • 6m
   • 1y
   • Max

   50.45+5.18 (+11.44%)

   at Fri, Jul 26, 2024, 4:00PM EDT - U.S. markets closed

   Delayed Quote

   • Open 48.27
   • High 50.61
   • Low 47.73
   • Prev. Close 45.27

   • 52 Wk. High 63.41
   • 52 Wk. Low 39.35
   • P/E N/A
   • Mkt. Cap 102.28B

   • NYSE
   • •Price in USD

4. www.bms.com › caBristol Myers Squibb - Global Biopharmaceutical Company

   www.bms.com › ca

   • Cached

   Learn more about Bristol Myers Squibb and our mission to discover, develop and deliver innovative medicines to patients with serious diseases.

5. www.bms.com › about-usAbout us - Bristol Myers Squibb

   www.bms.com › about-us

   • Cached

   We promote health equity and seek to improve the health outcomes of populations disproportionately affected by serious diseases. Learn about global biopharmaceutical innovator Bristol Myers Squibb, helping millions to fight cancer, cardiovascular disease, HIV/AIDS, and more.

6. ca.finance.yahoo.com › news › bristol-myers-secondBristol Myers second-quarter results beat expectations ...

   ca.finance.yahoo.com › news › bristol-myers-second

   • Cached

   1 day ago · Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis. "You're really seeing the transformation of our business to the new growth portfolio," Chief Financial Officer David Elkins said in an interview. Sales from its so ...

7. www.forbes.com › sites › greatspeculationsGrowth Portfolio Will Likely Drive Bristol Myers Squibb's Q2

   www.forbes.com › sites › greatspeculations

   • Cached

   1 day ago · Bristol Myers Squibb’s adjusted gross margin declined by 230 bps y-o-y to 77.8% in Q1’24, partly due to product mix. Bristol Myers Squibb recorded a one-time charge of $12.1 billion for the ...

8. news.bms.comBristol Myers Squibb - News

   news.bms.com

   Jun 21, 2024 · Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial